Ruzotolimod

Overview

Ruzotolimod (RO7020531) is an orally active TLR7 agonist. Ruzotolimod inhibits WHV viral replication and, in combination with RO-7049389 ( HY-145579 ), inhibits AAV-HBV viral load. Ruzotolimod can be used to study infection with COVID-19 or SARS-CoV-2 .

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Viral Infection | Products > Disease Areas > Pain | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Infection | Products > Signaling Pathways > Toll-like Receptor (TLR) | Products > Signaling Pathways > SARS-CoV | Products > Signaling Pathways > HBV

Product Information

• Catalog No.: HY-145592
• CAS No.: 1948241-60-8
• Molecular Formula: C14H18N4O5S
• Molecular Weight: 354.38
• Purity: 99.92%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source